Andere Sprachen MAIA Biotechnology, Inc.

Aktien

A3DGQQ

US5526411021

MAIA

Markt geschlossen - Nyse Andere Börsenplätze 22:00:00 31.05.2024			% 5 Tage	% 1. Jan.
4,75 ^USD	+8,20 %		+27,01 %	+305,98 %

14.05.	MAIA Biotechnology, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI
26.04.	Maia Biotechnology Insider kaufte Aktien im Wert von $299,409, laut einer aktuellen SEC Einreichung	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

MAIA Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14.05.
Maia Biotechnology Insider Bought Shares Worth $299,409, According to a Recent SEC Filing	26.04.
MAIA Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21.03.
MAIA Biotechnology, Inc. Appoints Saadettin Kilickap to its Scientific Advisory Board	21.03.
MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients	08.03.
MAIA Biotechnology, Inc. Announces Positive Efficacy Data for Third-Line Treatment in its Phase 2 THIO-101 Clinical Trial Evaluating THIO Sequenced with CPI Cemiplimab in Advanced NSCLC	06.03.
MAIA Biotechnology, Inc. Appoints Remus Vezan to its Scientific Advisory Board	27.02.
MAIA Biotechnology, Inc. Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer	22.02.
MAIA Biotechnology, Inc. Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer	07.02.
Maia Biotechnology, Inc. Announces Publication of International Pct Patent Application Covering Anticancer Telomere-Targeting Compounds	24.01.
MAIA Biotechnology, Inc. Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024	17.01.
Top Premarket Decliners	12.01.
MAIA Biotechnology, Inc. Announces Dose Selection in Thio-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer	19.12.
MAIA Biotechnology Closes $4 Million Direct Offering	17.11.
Top Midday Decliners	15.11.
FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma	13.11.
MAIA Biotechnology Says Glioblastoma Treatment Gets Orphan-Drug Designation From US FDA	10.11.
MAIA Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07.11.
MAIA Biotechnology, Inc. Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial	24.10.23
MAIA Biotechnology, Inc. Reveals New Data Showing THIO's Potent Anticancer Activity in Aggressive Pediatric Brain Cancer	12.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen MAIA Biotechnology, Inc.

Aktien

A3DGQQ

US5526411021

MAIA

Andere Sprachen

Filter